RxDoctor Payments Data

Samantha Boggs, NP

Gerontology · Galveston, TXNPI 1124568324

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,806 of the $14,821 with a category attached, or 66.2%. Gilead accounts for 95.3% of it on its own, with 3 other manufacturers making up the rest. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,821in general payments, 2019–2025

Across 56 payments — averaging $264.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$14K
  • AbbVie$525
  • Albireo Pharma, Inc.$140
  • Novartis$27

What the payments were for

  • Speaking & faculty fees$9,80666%
  • Travel & lodging$3,44923%
  • Food & beverage$1,56611%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead30$14,128
AbbVie24$525
Albireo Pharma, Inc.1$140
Novartis1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,821 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$10,703
Medicare patients
86
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin49$173,974
VemlidyTenofovir Alafenamide16$44,823
LinzessLinaclotide12$10,815
Azathioprine11$2,941
Omeprazole60$1,436
Ursodiol18$1,377
Lactulose33$1,019
Famotidine59$900
Pantoprazole Sodium62$853
ConstuloseLactulose12$254
Spironolactone20$248
Furosemide23$55
Propranolol Hcl17$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$14,128$44,82316 claims
AbbVieLinzess$525$10,81512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.

Other gerontology in Galveston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →